BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Celltrion Launches 300 mg Omlyclo Omalizumab Biosimilar Across Key European Markets

Omlyclo® (omalizumab) 300 mg launched in key European markets including Germany, the UK and France, with rollout to expand across Europe by ye...

August 26, 2026 | News

Biocon Partners with Innomar Strategies to Strengthen Canada Supply Chain

Biocon has partnered with Innomar Strategies, a healthcare services and logistics company, to strengthen its pharmaceutical supply chain and distribution n...

August 25, 2026 | News

Taiwan’s Anbogen Partners University of Tokyo to Advance ABT-301 Across Solid Tumours

Anbogen Therapeutics Inc. (TPEx: 7784) ("Anbogen" or the "Company"), a clinical-stage precision oncology company, announced that it has entered into a Coll...

August 25, 2026 | News

South Korea’s Rznomics Joins Lilly Gateway Labs in US to Accelerate RNA Gene Therapies

Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining Lilly ...

August 25, 2026 | News

South Korea’s Hanmi Pharm Licenses Obesity Drug HM17321 to Genentech in $2.3B Deal

HM17321, a proprietary UCN2 (urocortin-2) analog, is being developed as a treatment for chronic-weight management and associated conditions, including ob...

August 25, 2026 | News

Lōkahi Therapeutics Expands ai² Futures Lab Collaboration with University of Georgia

Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), announced the continued participation of the University of Georgia&rsqu...

August 24, 2026 | News

Akeso Secures China Clinical Trial Clearance for B7-H3 ADC AK157D1

Akeso, Inc. announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearanc...

August 24, 2026 | News

Leads Biolabs’ Opamtistomig NDA Accepted in China for Advanced EP-NEC

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the Center for Drug Evaluation (CDE) of China'...

August 24, 2026 | News

CureGene Doses First Subject in Australia Phase I Trial of Oral Metabolic Drug CG-0416

CureGene recently announced that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-β agonist...

August 24, 2026 | News

Harbour BioMed Secures China IND Approval for HBM7004 Bispecific Antibody in Advanced Solid Tumours

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics i...

August 20, 2026 | News

Singapore HSA Approves GSK’s Blenrep Combinations for Relapsed or Refractory Multiple Myeloma

Two head-to-head phase III trials demonstrated superior efficacy, including overall survival versus a daratumumab-based triplet in DREAMM-7 Blenrep, a f...

August 20, 2026 | News

OncoC4 Doses First Patient in Phase I Trial of neoCD24-Targeting T-Cell Engager ONC-783

— ONC-783 is the first-and-only clinical-stage T-cell engager targeting a cancer-specific glycoform of CD24 (neoCD24) — — Subcutaneous f...

August 19, 2026 | News

Connext Completes Phase 2 Enrollment of CNT201 for Dupuytren’s Contracture

All 56 planned participants enrolled approximately five months after first patient dosing - Topline Phase 2 data expected in late 2026 - Positive d...

August 19, 2026 | News

Henlius, Sandoz Expand Global Biosimilars Alliance with Up to 10 New Antibody Assets

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs...

August 18, 2026 | News

Stay Connected